DK-233(Rifampicin) Bioequivalence study -Bioequivalence of DK-233 150 mg capsules and DK-233 20 mg/ml syrup in healthy Japanese subjects-

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1080223619

Enrollment

Registered

2017-08-18

Start date

2017-08-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers

Interventions

investigational material(s) Generic name etc : DK-233 syrup INN of investigational material : rifampicin Therapeutic category code : 616 Antibiotic preparations acting mainly on acid-fast bacteria Dos

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1)Japanese male 2)Aged 20 years to 45 years (inclusive), at the time of informed consent 3)Body mass index (BMI; calculated by body weight [kg]/height [m]2) in the range of >= 18.5 kg/m2 and < 25.0 kg/m2 at the screening examination

Exclusion criteria

Exclusion criteria: 1)Hypersensitivity or idiosyncratic reactions to a drug (such as penicillin allergy) 2)Presence or history of any drug abuse or of alcohol abuse etc.

Design outcomes

Primary

Measure	Time frame
Pharmacokinetics and safety	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026